stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) P/B ratio
As of 5 November 2026, GSK PLC Sponsored ADR (GSK) trades at a P/B ratio of 4.1×. Over the past ten years it has ranged from 2.0× (September 2022) to 27.5× (September 2019); the current reading is higher than 24% of that period. That is below the Drug Manufacturers General industry median of 5.2× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 4.7× | 14.51% |
| FY2024 | 4.1× | (13.66%) |
| FY2023 | 4.8× | (16.06%) |
| FY2022 | 5.7× | 51.32% |
| FY2021 | 3.8× | 9.70% |
| FY2020 | 3.4× | (30.89%) |
| FY2019 | 5.0× | (74.11%) |
| FY2018 | 19.2× | (4.53%) |
| FY2017 | 20.1× | 42.78% |
| FY2016 | 14.1× | 144.28% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 3.9× | (14.32%) |
| Jun 2026 | 4.6× | (3.49%) |
| Mar 2026 | 4.7× | 0.17% |
| Dec 2025 | 4.7× | 15.14% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| SNY Sanofi compare | 1.4× |
| BIIB Biogen Inc. compare | 1.9× |
| PFE Pfizer Inc. compare | 1.9× |
| GSK GSK PLC Sponsored ADR | 4.1× |
| NVO Novo Nordisk A/S compare | 5.2× |
| BMY Bristol Myers Squibb Company compare | 5.5× |
| AZN AstraZeneca PLC compare | 5.6× |
| GILD Gilead Sciences, Inc. compare | 16.1× |
| AMGN Amgen Inc. compare | 21.4× |
| Drug Manufacturers General industry median | 5.2× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement